Glaucoma, Angle-Closure, Glaucoma Capsulare, Glaucoma Congenital, Glaucoma; Drugs, Glaucoma Eye, Glaucoma, Neovascular, Glaucoma Open-Angle, Glaucoma, Pigmentary, Glaucoma Secondary, Surgery
Conditions
Brief summary
The study is an observational analysis of patients' medical data recorded in a large-scale register, both retrospective (for patients operated and data recorded before 2018) and prospective (for data collected after 2018) in nature.Patients' medical data contained in the register will be analysed to determine the efficacy of the treatments they received during their follow-up at the investigation centre.
Detailed description
This study involves the creation and analysis of a large-scale register including all patients suffering from glaucoma, currently and previously followed-up and treated at a single tertiary centre in Lausanne, Switzerland. The design of the study is longitudinal, observational and comparative. Patients are recruited retrospectively if they attended the research centre before September 2018, and prospectively if they attend the centre from this month onwards. Their inclusion does not affect their care, treatment choice or follow-up. All data of recruited patients is be kept in their medical notes until a specific analysis is launched. Data is then exported from their medical notes into a coded database for analysis. At the end of each analysis session (defined as the publication of the related article), all exported data is fully anonymised. Data analysis will aim to assess the long-term efficacy, safety profile, and factors predictive of success/failure of treatments performed. To ensure the quality of all included data, health-related information will be extracted directly from the medical notes and coded into the register by a Clinical Research Associate. Conformity of the process and recorded data will be confirmed by regular internal auditing. For quality assurance the Ethics Committee may visit the research sites. Direct access to the source data and all project related files and documents must be granted on such occasions.
Interventions
None listed
Sponsors
Dr. Kaweh Mansouri
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
1 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of glaucoma (open-angle, closed-angle, primary or secondary) or ocular hypertension (IOP \> 24 mmHg, medicated or not) * Patients who received treatment (medical, laser or surgical) at the Glaucoma Centre, Montchoisi Clinic * Able and willing to provide informed written or verbal consent
Exclusion criteria
* Patient who are unable to understand the implications of their inclusion in the study or who are unable or unwilling to give informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with IOP reduction mmHg | 12 month | Final Intra Ocular Pressure \<20% compared to baseline |
| Patients with quantitative OCT variations ( RNFL, μm) | 12 month | Variation of RNFL before and after treatment ( laser, surgery, drug..) |
| Number of patients with quantitative VF variation ( MD, dB) | 12 month | Visual Field MD variation before and after treatment ( laser, surgery, drug..) |
| Number of patients with quantitative VF variation (LV, dB) | 12 months | Visual Field MD variation before and after treatment ( laser, surgery, drug..) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anterior segment OCT variations: AOD (mm) | 12 month | variations of these measurements before and after procedure ( surgery or laser) |
| Number of operations received by a patients | 12 month | Number of operations undertaken by each patient |
| Anterior segment OCT variations: TISA (mm2) | 12 month | variations of these measurements before and after procedure ( surgery or laser) |
| Number of patients undergoing a specific ocular surgical or laser procedure | 12 month | Number of patients undertaking different types of ocular procedures ( deep sclerectomy, cataract, LPI, SLT,...) |
| Number of lowering IOP drugs ( molecules) taken by each patient | 12 month | Number of molecules used by each patient (e.g Cosopt: 2 molecules, Xalatan: 1...) |
| Anterior segment OCT variations: ACA (°), SSA (°) | 12 month | variations of these measurements before and after procedure ( surgery or laser) |
Countries
Switzerland
Outcome results
None listed